{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:18:22Z","timestamp":1694996302914},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.transproceed.2017.11.019","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T00:35:58Z","timestamp":1517618158000},"page":"246-249","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of High-Risk Acute Myeloid Leukemia With Cladribine, Cytarabine, Mitoxantrone, and Granulocyte Colony-Stimulating Factor Then Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series"],"prefix":"10.1016","volume":"50","author":[{"given":"J.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2017.11.019_bib1","first-page":"2465","article-title":"Agents for refractory\/relapsed acute lymphocytic leukemia in adults","volume":"18","author":"Qian","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.transproceed.2017.11.019_bib2","first-page":"665","article-title":"Current approaches in the treatment of relapsed and refractory acute myeloid leukemia","volume":"4","author":"Ramos","year":"2015","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.transproceed.2017.11.019_bib3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4155\/cli.11.24","article-title":"New considerations in the design of clinical trials for the treatment of acute leukemia","volume":"1","author":"Hourigan","year":"2011","journal-title":"Clin Investig (Lond)"},{"key":"10.1016\/j.transproceed.2017.11.019_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/1042819021000035608","article-title":"Purine nucleoside analogues in the treatment of myeloid leukemias","volume":"44","author":"Robak","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.transproceed.2017.11.019_bib5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V87.1.256.256","article-title":"Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions","volume":"87","author":"Gandhi","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2017.11.019_bib6","first-page":"1563","article-title":"Clinical and laboratory studies of 2-chlorodeoxyadenosine\u00a0+\/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults","volume":"10","author":"Kornblau","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.transproceed.2017.11.019_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.leukres.2014.01.005","article-title":"Cladribine in the treatment of acute myeloid leukemia","volume":"38","author":"Robak","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.transproceed.2017.11.019_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1034\/j.1600-0609.2003.00122.x","article-title":"A\u00a0multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG)","volume":"71","author":"Wrzesien-Kus","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.transproceed.2017.11.019_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-0609.2007.00988.x","volume":"80","author":"Wierzbowska","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.transproceed.2017.11.019_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.beha.2013.10.005","article-title":"Relapsed acute myeloid leukemia: Why is there no standard of care?","volume":"26","author":"Ravandi","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.transproceed.2017.11.019_bib11","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood.V106.11.546.546","article-title":"Very poor survival of patients with AML who relapse after achieving a first complete remission: the Eastern Cooperative Oncology Group Experience","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2017.11.019_bib12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-005-1046-0","volume":"84","author":"Wrzesien-Kus","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.transproceed.2017.11.019_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428190009053545","article-title":"Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia","volume":"39","author":"Robak","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.transproceed.2017.11.019_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2017.11.019_bib15","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s00277-014-2143-8","article-title":"Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia","volume":"93","author":"De Astis","year":"2014","journal-title":"Ann Hematol"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517308370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517308370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T11:14:15Z","timestamp":1635506055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134517308370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0041134517308370"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.11.019","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of High-Risk Acute Myeloid Leukemia With Cladribine, Cytarabine, Mitoxantrone, and Granulocyte Colony-Stimulating Factor Then Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}